BIAF

bioAffinity Technologies' stock (BIAF) has experienced a stock price increase, with shares increasing by 72.0% since the beginning of the year. The company reported its first-quarter 2026 results, with a net loss of ($0.81) per share and revenue of $1.35 million, and full-year 2025 earnings showed a loss of US$8.66 per share. bioAffinity Technologies launched a new study to expand the use of CyPath® Lung technology for asthma and COPD diagnosis and treatment, and multiple case studies highlighting CyPath® Lung's effectiveness were published. The company initiated a large-scale, longitudinal clinical study for CyPath® Lung, partially funded by the U.S. Department of Defense. bioAffinity Technologies announced it had regained compliance with all applicable Nasdaq listing requirements, and the company's stock underwent a 1-for-30 reverse split on September 19, 2025. The company has been strategically discontinuing certain unprofitable pathology services to focus on higher-margin services, particularly CyPath® Lung testing.